RELAPSED CANCER

This study tests whether adding a new drug called roginolisib to two standard drugs (venetoclax and rituximab) can better control relapsed or refractory chronic lymphocytic leukemia (CLL). About 64 adults who have already tried at least two prior treatments will receive the combi…

This study tests a two-drug combination (zanubrutinib and pemetrexed) followed by a maintenance drug for people whose central nervous system lymphoma has returned or stopped responding to treatment. About 15 adults with this rare brain lymphoma will receive the drugs to see if tu…

This study tests whether teclistamab, a drug for relapsed or refractory multiple myeloma, can be given safely in an outpatient setting instead of the hospital. It involves 15 patients who have tried at least three prior treatments. The goal is to develop clear procedures for outp…

This study is for people whose B-cell cancers (like certain lymphomas) have come back or not responded to treatment. It tests a new drug called BGB-16673, which breaks down a protein that helps cancer grow, combined with other cancer drugs. The goal is to find safe doses and see …

This study tests a combination of the immunotherapy drug epcoritamab with standard chemotherapy (GDP) in 32 adults whose large B-cell lymphoma has returned or not responded to treatment. The goal is to see if the combo can shrink tumors enough to allow for a stem cell transplant …

This study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…